Long-acting erythropoietin: clinical studies and potential uses in neonates

Aranesp (darbepoietin alfa) is a biologically modified form of recombinant human erythropoietin (rHuEpo). Two additional carbohydrate-binding sites give Aranesp a half-life about three times that of rHuEpo. Extensive studies in adults and early studies in children indicate that Aranesp can be administered far less frequently than rHuEpo with an equivalent erythropoietic effect.This article reviews these studies and reports on the in vitro effects of Aranesp on human fetal and neonatal erythroid progenitors.